Market Overview

IPM Chirana Announces U.S. Headquarters and Global Launch of Aura V Critical Care Ventilators

Share:

IPM Chirana accelerates U.S. manufacturing of ICU ventilators to combat the effects of COVID-19

RESEARCH TRIANGLE PARK, N.C. (PRWEB) November 16, 2020

IPM Chirana today announced the location of its U.S. headquarters in Research Triangle Park, NC, as well as the commencement of production of Aura V critical care ventilators at the SMTC facility in Boston, MA.

"These milestones are part of our mission to improve healthcare outcomes by providing clinicians around the world with cutting edge, patient-centric solutions like the Aura V ICU ventilator," said Bud Reeves, CEO. "We are very excited to establish our headquarters in the prestigious Research Triangle Park area. Furthermore, we are proud of SMTC's accomplishment of implementing our accelerated production plan and are proceeding to manufacture at least 300 Aura V ventilators by year-end."

The Aura V ventilator is designed for use in intensive care units to support and protect the patient's lungs while providing critical information to caregivers. Its ventilation support range is comprehensive for neonates to adults. It provides supportive breathing assistance to complete mechanical ventilation, all in one system.

"The Aura V ventilator is one of the most technologically advanced critical care ventilators in the world," said Mike Gentile, Vice President of Medical Affairs. "With the ongoing COVID-19 pandemic and a worldwide shortage, our contribution to the global production of ICU ventilators is crucial. Many more patients and clinicians will benefit from the Aura V ventilator's sophisticated, unique technology that optimizes patient care."

IPM Chirana was formed as a strategic partnership between Europe's leading infratech asset manager IPM Group and Slovak company Chirana Medical to rapidly accelerate global production of Aura V ventilators. The Aura V ventilator has been available for years in the EU and other parts of the world. Recently, the Aura V ventilator received emergency ANVISA marketing authorization in Brazil. Applications for use in the U.S. and Canada are currently in review.

"We believe the world does not need more cheap ventilators; the world needs better ventilators," said Peter Gajdos, IPM Chirana Executive Chairman and Head of Venture Capital at IPM Group. "IPM Chirana is composed of exceptionally knowledgeable leaders in their respective fields and together, we are committed to delivering the most advanced critical care ventilator to patients and caregivers."

For more information about IPM Chirana, visit their newly launched website at IPMChirana.com.

###

About IPM Chirana

IPM Chirana is a global provider of life-changing medical technologies based in Research Triangle Park, North Carolina, with a manufacturing facility in Boston, Massachusetts. Led by knowledgeable leaders in respiratory care, we are focused on offering the Aura V ventilator's unique capabilities globally. Through our unwavering commitment, we empower and guide healthcare providers in their quest to improve and protect the health, safety and quality of life for patients around the world. Through our collaboration and unified efforts, we invest our resources to nurture and advance knowledge and the adoption of evidence-based, reliable and robust innovation.

For the original version on PRWeb visit: https://www.prweb.com/releases/ipm_chirana_announces_u_s_headquarters_and_global_launch_of_aura_v_critical_care_ventilators/prweb17546530.htm

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com